Randomized Phase II Study of Dacomitinib (PF-00299804), an...

Journal of Clinical Oncology 2012 / 09 Vol. 30; Iss. 27

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

Ramalingam, S. S., Blackhall, F., Krzakowski, M., Barrios, C. H., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D. C., Frank, R., Letrent, S. P., Ruiz-Garcia, A., Taylor, I., Liang, J. Q., Ca
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2011.40.9433
Date:
September, 2012
File:
PDF, 194 KB
english, 2012
Conversion to is in progress
Conversion to is failed